DE60029242D1 - Arzneien zur begleitenden behandlung von glaukomen - Google Patents

Arzneien zur begleitenden behandlung von glaukomen

Info

Publication number
DE60029242D1
DE60029242D1 DE60029242T DE60029242T DE60029242D1 DE 60029242 D1 DE60029242 D1 DE 60029242D1 DE 60029242 T DE60029242 T DE 60029242T DE 60029242 T DE60029242 T DE 60029242T DE 60029242 D1 DE60029242 D1 DE 60029242D1
Authority
DE
Germany
Prior art keywords
glaucomes
drugs
complementary treatment
active ingredients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60029242T
Other languages
English (en)
Other versions
DE60029242T2 (de
Inventor
Tomihisa Yokoyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of DE60029242D1 publication Critical patent/DE60029242D1/de
Application granted granted Critical
Publication of DE60029242T2 publication Critical patent/DE60029242T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE60029242T 1999-12-01 2000-12-01 Arzneien zur begleitenden behandlung von glaukomen Expired - Fee Related DE60029242T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP34152499 1999-12-01
JP34152499 1999-12-01
JP2000078769 2000-03-21
JP2000078769 2000-03-21
PCT/JP2000/008545 WO2001039805A1 (fr) 1999-12-01 2000-12-01 Coprescription pour le traitement du glaucome

Publications (2)

Publication Number Publication Date
DE60029242D1 true DE60029242D1 (de) 2006-08-17
DE60029242T2 DE60029242T2 (de) 2007-07-05

Family

ID=26576988

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60029242T Expired - Fee Related DE60029242T2 (de) 1999-12-01 2000-12-01 Arzneien zur begleitenden behandlung von glaukomen

Country Status (22)

Country Link
US (4) US7307096B2 (de)
EP (3) EP1234582B1 (de)
JP (1) JP4000505B2 (de)
KR (3) KR20040045029A (de)
CN (3) CN1615880A (de)
AT (1) ATE332145T1 (de)
AU (1) AU773110B2 (de)
BR (1) BR0015980A (de)
CA (1) CA2392804C (de)
CZ (1) CZ20021829A3 (de)
DE (1) DE60029242T2 (de)
ES (1) ES2267586T3 (de)
HK (1) HK1047239B (de)
HU (1) HUP0204049A3 (de)
IL (2) IL149444A0 (de)
MX (1) MXPA02005505A (de)
NO (1) NO20022584L (de)
NZ (1) NZ518930A (de)
PL (1) PL201783B1 (de)
RU (4) RU2002114335A (de)
TW (1) TWI290470B (de)
WO (1) WO2001039805A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386611A4 (de) * 2001-04-19 2009-05-13 Teika Pharmaceutical Co Ltd Medizinprodukte und medizinische sets
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP5222462B2 (ja) * 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
WO2005079809A1 (ja) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. 澄明なラタノプロスト点眼液
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
KR20130139748A (ko) * 2010-05-07 2013-12-23 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 안과용 조성물
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR101327267B1 (ko) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 엔드이펙터용 구동력 전달장치
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents
CN107106570B (zh) * 2014-12-12 2021-02-05 兴和株式会社 水性组合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS536156B2 (de) 1972-10-30 1978-03-04
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
EP0189690B1 (de) * 1984-12-12 1989-03-01 Merck & Co. Inc. Substituierte aromatische Sulfonamide, ihre Herstellung und diese enthaltende ophthalmische Zubereitungen
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (ja) * 1987-07-22 1997-05-14 エーザイ株式会社 高眼圧症治療用点眼剤
JPS6426518U (de) 1987-08-11 1989-02-15
EP0364417B9 (de) 1988-09-06 2004-10-06 Pharmacia AB Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
JP3045511B2 (ja) 1988-09-09 2000-05-29 ドレナート、クラウス 人工腰関節およびその使用
EP0375299A1 (de) * 1988-12-19 1990-06-27 Merck & Co. Inc. Mischungen von ACE- und CA-Inhibitoren zur Behandlung von Glaucoma
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
US5250521A (en) 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
CA2129037C (en) * 1992-02-21 1998-03-24 Thomas Robert Dean Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
WO1995021609A1 (en) * 1994-02-08 1995-08-17 Ciba-Geigy Ag Treatment of normotensive glaucoma with angiotensin ii antagonists
EP1110551B1 (de) * 1994-03-16 2004-05-12 Sankyo Company Limited Okulares Hypotonikum
CA2185524C (en) * 1994-03-16 2006-12-05 Tomihisa Yokoyama Ocular tension depressant
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
RU2188013C2 (ru) * 1996-04-05 2002-08-27 Такеда Кемикал Индастриз, Лтд. Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO1998050024A1 (en) 1997-05-09 1998-11-12 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
CZ300553B6 (cs) * 1999-06-11 2009-06-17 Sankyo Company Limited Místne podávané prostredky ke snížení nitroocního tlaku

Also Published As

Publication number Publication date
PL201783B1 (pl) 2009-05-29
KR20020058034A (ko) 2002-07-12
AU773110B2 (en) 2004-05-20
JP2001335511A (ja) 2001-12-04
WO2001039805A1 (fr) 2001-06-07
RU2004111359A (ru) 2005-09-20
RU2299067C2 (ru) 2007-05-20
US20050043383A1 (en) 2005-02-24
TWI290470B (en) 2007-12-01
MXPA02005505A (es) 2002-09-02
DE60029242T2 (de) 2007-07-05
IL149444A0 (en) 2002-11-10
CZ20021829A3 (cs) 2002-08-14
CA2392804C (en) 2009-02-03
AU1557501A (en) 2001-06-12
EP1234582B1 (de) 2006-07-05
RU2004111358A (ru) 2005-09-20
CN1407903A (zh) 2003-04-02
NO20022584D0 (no) 2002-05-31
EP1344535A2 (de) 2003-09-17
KR20040045028A (ko) 2004-05-31
EP1344534A3 (de) 2004-01-02
US20080221184A1 (en) 2008-09-11
PL355431A1 (en) 2004-04-19
CN1263512C (zh) 2006-07-12
JP4000505B2 (ja) 2007-10-31
CN1615880A (zh) 2005-05-18
HUP0204049A2 (hu) 2003-04-28
NO20022584L (no) 2002-07-29
KR20040045029A (ko) 2004-05-31
CN1615879A (zh) 2005-05-18
ES2267586T3 (es) 2007-03-16
EP1234582A1 (de) 2002-08-28
RU2004111357A (ru) 2005-09-20
ATE332145T1 (de) 2006-07-15
EP1344534A2 (de) 2003-09-17
EP1234582A4 (de) 2003-05-07
HUP0204049A3 (en) 2006-07-28
US20030040529A1 (en) 2003-02-27
BR0015980A (pt) 2002-11-12
US7307096B2 (en) 2007-12-11
NZ518930A (en) 2003-09-26
RU2002114335A (ru) 2004-01-10
KR100607430B1 (ko) 2006-08-02
EP1344535A3 (de) 2004-01-28
CA2392804A1 (en) 2001-06-07
HK1047239A1 (en) 2003-02-14
HK1047239B (zh) 2006-12-08
IL149444A (en) 2007-06-17
US20050014808A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE284388T1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
DE60005471D1 (de) EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose
ATE339425T1 (de) Platelet adp rezeptor inhibitoren
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
DE60228317D1 (de) N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
DE60222168D1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
ATE279113T1 (de) Hypoxanthin- und thiohypxanthin-verbindungen
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee